Oct 24, 2022 / 12:00PM GMT
Operator
Good morning. My name is Olivia, and I'll be your conference operator today. At this time, I would like to welcome everyone to Vaxcyte's VAX-24 Phase I/II Proof-of-Concept Study Results of Conference Call. (Operator Instructions) I would now like to turn the call over to Andrew Guggenheim, President and Chief Financial Officer of Vaxcyte.
Andrew L. Guggenhime - Vaxcyte, Inc. - President & CFO
Great. Thanks, everyone, and thanks, operator, and good morning, everyone. I'd like to welcome you to Vaxcyte's conference call to discuss top line results from our Phase I/II Proof-of-Concept Study, evaluating the safety, tolerability and immunogenicity of VAX-24, the company's investigational 24-valent pneumococcal conjugate vaccine in healthy adults aged 18 to 64.
I'm joined this morning by our Chief Executive Officer, Grant Pickering; and our Chief Operating Officer, Jim Wassil. Early this morning, we issued a news release announcing our top line results and the presentation, we will be reviewing today, will be made available shortly on our website and via
Vaxcyte Inc VAX-24 Phase 1/2 Proof-of-Concept Study Topline Data Call Transcript
Oct 24, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers